amiodarone has been researched along with Cirrhosis in 10 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone (AMD), a medicine used to treat life-threatening arrhythmias, is frequently linked to pulmonary fibrosis (PF)." | 8.31 | Suppressing NLRP3 activation and PI3K/AKT/mTOR signaling ameliorates amiodarone-induced pulmonary fibrosis in rats: a possible protective role of nobiletin. ( Abdelhamid, WG; El Tabaa, MM; Elgharabawy, RM, 2023) |
| "Amiodarone is a di-iodated benzofuran derivative that is commonly used to treat patients with various cardiac arrhythmias." | 7.79 | [A case of simultaneously occurred amiodarone-induced hepatitis and hypothyroidism]. ( Chae, HB; Cho, YS; Han, JH; Kang, KM; Kim, JS; Lim, JC; Park, SM, 2013) |
| "By preventing isoprenaline induced myocardial injury and fibrosis, amiodarone may have a cardioprotective role." | 7.69 | Amiodarone protection against myocardial injury and fibrosis induced by isoprenaline is abolished by thyroid hormone. ( Cespedes, C; Dussaillant, G; Jalil, JE, 1994) |
| "Amiodarone is effective in treating persistent atrial fibrillation compared with other antiarrhythmic drugs." | 5.33 | Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model. ( Ashikaga, K; Furukawa, K; Iwasa, A; Kimura, M; Kobayashi, T; Motomura, S; Okumura, K; Owada, S; Sasaki, S, 2006) |
| "Amiodarone (AMD), a medicine used to treat life-threatening arrhythmias, is frequently linked to pulmonary fibrosis (PF)." | 4.31 | Suppressing NLRP3 activation and PI3K/AKT/mTOR signaling ameliorates amiodarone-induced pulmonary fibrosis in rats: a possible protective role of nobiletin. ( Abdelhamid, WG; El Tabaa, MM; Elgharabawy, RM, 2023) |
| "Amiodarone is a di-iodated benzofuran derivative that is commonly used to treat patients with various cardiac arrhythmias." | 3.79 | [A case of simultaneously occurred amiodarone-induced hepatitis and hypothyroidism]. ( Chae, HB; Cho, YS; Han, JH; Kang, KM; Kim, JS; Lim, JC; Park, SM, 2013) |
| "By preventing isoprenaline induced myocardial injury and fibrosis, amiodarone may have a cardioprotective role." | 3.69 | Amiodarone protection against myocardial injury and fibrosis induced by isoprenaline is abolished by thyroid hormone. ( Cespedes, C; Dussaillant, G; Jalil, JE, 1994) |
| "Amiodarone is a potent and efficacious antiarrhythmic agent, yet associated with its use are life-threatening pulmonary fibrosis and hepatotoxicity." | 3.68 | Repeated amiodarone exposure in the rat: toxicity and effects on hepatic and extrahepatic monooxygenase activities. ( Brien, JF; Daniels, JM; Leeder, RG; Massey, TE, 1990) |
| "Based on this case amiodarone-related pneumonitis will be discussed, which due to a lack of pathognomonic symptoms is often difficult to diagnose and for which there are few treatment options available." | 1.35 | [Amiodarone-induced pneumonitis. Lethal complication in a patient after thoracic surgery]. ( Fisseler-Eckhoff, A; Ghezel-Ahmadi, V; Kürschner, VC; Obenhaus, T; Schirren, J; Schmitz, JE, 2008) |
| "Amiodarone is effective in treating persistent atrial fibrillation compared with other antiarrhythmic drugs." | 1.33 | Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model. ( Ashikaga, K; Furukawa, K; Iwasa, A; Kimura, M; Kobayashi, T; Motomura, S; Okumura, K; Owada, S; Sasaki, S, 2006) |
| "Amiodarone, 150 mg, was injected over 15 seconds intravenously into 9 patients, 52 +/- 9 years of age, weighing between 65 and 98 kg (mean = 81 +/- 15." | 1.30 | Amiodarone concentration in human myocardium after rapid intravenous administration. ( Agapitos, E; Alexopoulos, G; Anastasiou-Nana, MI; Karli, JN; Margari, ZJ; Nanas, JN; Patsi, EN; Stamatelopoulos, SF, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 3 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harb, I | 1 |
| Ashour, H | 1 |
| Rashed, LA | 1 |
| Mostafa, A | 1 |
| Samir, M | 1 |
| Aboulhoda, BE | 1 |
| El-Hanbuli, H | 1 |
| Rashwan, E | 1 |
| Mahmoud, H | 1 |
| El Tabaa, MM | 2 |
| Elgharabawy, RM | 1 |
| Abdelhamid, WG | 1 |
| Arunachalam, K | 1 |
| Maan, A | 1 |
| Chu, A | 1 |
| Cho, YS | 1 |
| Han, JH | 1 |
| Chae, HB | 1 |
| Kim, JS | 1 |
| Kang, KM | 1 |
| Park, SM | 1 |
| Lim, JC | 1 |
| Hori, Y | 1 |
| Nakahara, S | 1 |
| Mine, S | 1 |
| Anjo, N | 1 |
| Fujii, A | 1 |
| Ueda, Y | 1 |
| Taguchi, I | 1 |
| Ghezel-Ahmadi, V | 1 |
| Kürschner, VC | 1 |
| Fisseler-Eckhoff, A | 1 |
| Schirren, J | 1 |
| Schmitz, JE | 1 |
| Obenhaus, T | 1 |
| Ashikaga, K | 1 |
| Kobayashi, T | 1 |
| Kimura, M | 1 |
| Owada, S | 1 |
| Sasaki, S | 1 |
| Iwasa, A | 1 |
| Furukawa, K | 1 |
| Motomura, S | 1 |
| Okumura, K | 1 |
| Dussaillant, G | 1 |
| Jalil, JE | 1 |
| Cespedes, C | 1 |
| Anastasiou-Nana, MI | 1 |
| Nanas, JN | 1 |
| Alexopoulos, G | 1 |
| Karli, JN | 1 |
| Margari, ZJ | 1 |
| Agapitos, E | 1 |
| Patsi, EN | 1 |
| Stamatelopoulos, SF | 1 |
| Daniels, JM | 1 |
| Leeder, RG | 1 |
| Brien, JF | 1 |
| Massey, TE | 1 |
1 review available for amiodarone and Cirrhosis
| Article | Year |
|---|---|
Atrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and Management.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiomyopathy | 2020 |
9 other studies available for amiodarone and Cirrhosis
| Article | Year |
|---|---|
Nicorandil mitigates amiodarone-induced pulmonary toxicity and fibrosis in association with the inhibition of lung TGF-β1/PI3K/Akt1-p/mTOR axis in rats.
Topics: Amiodarone; Animals; Fibrosis; Lung; Mammals; Nicorandil; Phosphatidylinositol 3-Kinase; Phosphatidy | 2023 |
Suppressing NLRP3 activation and PI3K/AKT/mTOR signaling ameliorates amiodarone-induced pulmonary fibrosis in rats: a possible protective role of nobiletin.
Topics: Amiodarone; Animals; Fibrosis; NLR Family, Pyrin Domain-Containing 3 Protein; Phosphatidylinositol 3 | 2023 |
[A case of simultaneously occurred amiodarone-induced hepatitis and hypothyroidism].
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Chemical and Drug Induced Liver Injury; Female; Fibrosis; Hu | 2013 |
Pathological autopsy of a patient that underwent a successful ablation of an electrical storm from the left ventricular summit.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Autopsy; Catheter Ablation; Electrocardiography; Electroph | 2016 |
[Amiodarone-induced pneumonitis. Lethal complication in a patient after thoracic surgery].
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; F | 2008 |
Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model.
Topics: Action Potentials; Administration, Oral; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrill | 2006 |
Amiodarone protection against myocardial injury and fibrosis induced by isoprenaline is abolished by thyroid hormone.
Topics: Amiodarone; Animals; Fibrosis; Fluorescent Antibody Technique; Heart; Isoproterenol; Male; Myocardiu | 1994 |
Amiodarone concentration in human myocardium after rapid intravenous administration.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Body Weight; Cardiomyopathy, Dilated; Female; Fibro | 1999 |
Repeated amiodarone exposure in the rat: toxicity and effects on hepatic and extrahepatic monooxygenase activities.
Topics: Amiodarone; Animals; Biotransformation; Body Weight; Drug Administration Schedule; Fibrosis; Injecti | 1990 |